HRP20201262T1 - Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze - Google Patents
Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze Download PDFInfo
- Publication number
- HRP20201262T1 HRP20201262T1 HRP20201262TT HRP20201262T HRP20201262T1 HR P20201262 T1 HRP20201262 T1 HR P20201262T1 HR P20201262T T HRP20201262T T HR P20201262TT HR P20201262 T HRP20201262 T HR P20201262T HR P20201262 T1 HRP20201262 T1 HR P20201262T1
- Authority
- HR
- Croatia
- Prior art keywords
- morpholin
- yloxy
- phenyl
- pharmaceutically acceptable
- acetamide
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims 8
- 239000002469 receptor inverse agonist Substances 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims 17
- LNXDUSQEXVQFGP-UHFFFAOYSA-N n-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1NC(=O)CN1CCOCC1 LNXDUSQEXVQFGP-UHFFFAOYSA-N 0.000 claims 11
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 10
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 229960003530 donepezil Drugs 0.000 claims 5
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- LCPQCTBHZPMVFX-UHFFFAOYSA-N n-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide;dihydrochloride Chemical group Cl.Cl.C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1NC(=O)CN1CCOCC1 LCPQCTBHZPMVFX-UHFFFAOYSA-N 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical group [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims 2
- 229960003135 donepezil hydrochloride Drugs 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 229940125425 inverse agonist Drugs 0.000 claims 2
- 229960004136 rivastigmine Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- LWAJGASQEKHLCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid 2-morpholin-4-yl-N-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]acetamide Chemical compound OC(C(O)C(O)=O)C(O)=O.CC(C)N1CCC(CC1)Oc1ccc(NC(=O)CN2CCOCC2)cc1 LWAJGASQEKHLCH-UHFFFAOYSA-N 0.000 claims 1
- WRSZOMBMEGHKOJ-UHFFFAOYSA-N 2-morpholin-4-yl-n-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]acetamide Chemical compound C1CN(C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)CN1CCOCC1 WRSZOMBMEGHKOJ-UHFFFAOYSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- QPDVQLMRYAGBDM-UHFFFAOYSA-N N-[4-(1-cyclopropylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide 2,3-dihydroxybutanedioic acid Chemical compound OC(C(O)C(O)=O)C(O)=O.O=C(CN1CCOCC1)Nc1ccc(OC2CCN(CC2)C2CC2)cc1 QPDVQLMRYAGBDM-UHFFFAOYSA-N 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- HWVBCAJMEZQYSG-UHFFFAOYSA-N n-[4-(1-cyclopropylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(OC2CCN(CC2)C2CC2)C=CC=1NC(=O)CN1CCOCC1 HWVBCAJMEZQYSG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Kombinacija koja sadrži inverzni agonist histamin-3 receptora i inhibitor acetilholinesteraze; naznačena time da je inverzni agonist histamin-3 receptora izabran iz grupe koja se sastoji od:
N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida;
N-[4-(1-Ciklopropilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida; i
N-[4-(1-Izopropilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida;
ili njihove farmaceutski prihvatljive soli.
2. Kombinacija prema patentnom zahtjevu 1, naznačena time da je inhibitor acetilholinesteraze izabran iz grupe koja se sastoji od donepezila, rivastigmina i galantamina ili njihove farmaceutski prihvatljive soli.
3. Kombinacija prema patentnom zahtjevu 1, naznačena time da inverzni agonist histamin-3 receptora je N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegova farmaceutski prihvatljiva sol.
4. Kombinacija prema patentnom zahtjevu 1 ili patentnom zahtjevu 3, naznačena time da je farmaceutski prihvatljiva sol inverznog agonista histamin-3 receptora izabrana od
N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid dihidrohlorida;
N-[4-(1-Ciklopropilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid tartarata; i
N-[4-(1-Izopropilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid tartarata.
5. Kombinacija prema patentnom zahtjevu 1, 3 ili 4, naznačena time da inverzni agonist histamin-3 receptora je N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid dihidrohlorid.
6. Kombinacija prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time da inhibitor acetilholinesteraze je donepezil ili njegova farmaceutski prihvatljiva sol ili pri čemu, inhibitor acetilholinesteraze je donepezil hidrohlorid.
7. Kombinacija koja sadrži N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid dihidrohlorid i donepezil hidrohlorid.
8. Kombinacija prema bilo kojem od patentnih zahtjeva 1 do 7, za uporabu u liječenju kognitivnih poremećaja kod pacijenta.
9. Kombinacija za uporabu prema patentnom zahtjevu 8, naznačeno time da je kognitivni poremećaj izabran od Alzheimer-ove bolesti, šizofrenije, Parkinson-onove bolesti, demencije sa Lewy-telima, vaskularne demencije, frontotemporalne demencije, Down-ovog sindroma ili Tourette-ovog sindroma.
10. Spoj, N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il) acetamid ili njegova farmaceutski prihvatljiva sol za uporabu u kombinaciji sa inhibitorom acetilholinesteraze za liječenje Alzheimer-ove bolesti kod pacijenta.
11. Spoj za uporabu prema patentnom zahtjevu 10, kao dodatno liječenje kod pacijenta na stabilnom liječenju sa inhibitorom acetilholinesteraze.
12. Spoj za uporabu prema patentnom zahtjevu 10 ili patentnom zahtjevu 11, naznačen time da je inhibitor acetilholinesteraze izabran od donepezila, rivastigmina i galantamina ili njegove farmaceutski prihvatljive soli.
13. Spoj za uporabu prema patentnom zahtjevu 10 ili patentnom zahtjevu 11,
(a) naznačeno time da liječenje sadrži primjenu na pacijenta 0.1 mg do 100 mg N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida ili njegove farmaceutski prihvatljive soli na dan, ili
(b) time da liječenje sadrži primjenu na pacijenta 0.1 mg do 60 mg N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegove farmaceutski prihvatljive soli na dan, ili
(c) time da liječenje sadrži primjenu na pacijenta 0.1 mg do 30 mg N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegove farmaceutski prihvatljive soli na dan; ili
(d) time da liječenje sadrži primjenu na pacijenta 1 mg do 30 mg donepezila, ili farmaceutski prihvatljive soli na dan.
14. Farmaceutski pripravak koji sadrži kombinaciju prema bilo kojem od patentnih zahtjeva 1 do 7, i farmaceutski prihvatljive ekscipijente ili njihovu kombinaciju.
15. Farmaceutski pripravak prema patentnom zahtjevu 14, za uporabu u liječenju kognitivnih poremećaja izabranih od Alzheimer-ove bolesti, šizofrenije, Parkinson-onove bolesti, demencije sa Lewy-telima, vaskularne demencije i frontotemporalne demencije.
16. Farmaceutski pripravak prema patentnom zahtjevu 14 ili patentnom zahtjevu 15,
(a) naznačen time da N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegova farmaceutski prihvatljiva sol su prisutni u količini od 0.1 mg do 100 mg, ili
(b) time da N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegova farmaceutski prihvatljiva sol su prisutni u količini od 0.1 mg do 60 mg, ili
(c) time da N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamid ili njegova farmaceutski prihvatljiva sol su prisutni u količini od 0.1 mg to 30 mg; ili
(d) time da donepezil ili njegova farmaceutski prihvatljiva sol su prisutni u količini od 2 mg do 30 mg.
17. Spoj za uporabu prema patentnom zahtjevu 10, naznačen time da liječenje sadrži primjenu N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida ili njegove farmaceutski prihvatljive soli na pacijenta oralnim, nazalnim, lokalnim, dermalnim ili parenteralnim putevima.
18. Spoj za uporabu prema patentnom zahtjevu 10, naznačen time da liječenje sadrži primjenu N-[4-(1-Ciklobutilpiperidin-4-iloksi)fenil]-2-(morfolin-4-il)acetamida ili njegove farmaceutski prihvatljive soli na pacijenta jednom do tri puta na dan, jednom do tri puta tjedno ili jednom do tri puta mjesečno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028166 | 2016-08-18 | ||
| PCT/IB2017/054938 WO2018033847A1 (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
| EP17768234.1A EP3500253B1 (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201262T1 true HRP20201262T1 (hr) | 2020-12-11 |
Family
ID=59887325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201262TT HRP20201262T1 (hr) | 2016-08-18 | 2020-08-11 | Kombinacija inverzivnih agonista histamin-3 receptora sa inhibitorima acetilkolinesteraze |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10603323B2 (hr) |
| EP (1) | EP3500253B1 (hr) |
| JP (1) | JP6734470B2 (hr) |
| KR (1) | KR102039585B1 (hr) |
| CN (1) | CN109640975B (hr) |
| AU (1) | AU2017313427B2 (hr) |
| BR (1) | BR112019002645A2 (hr) |
| CA (1) | CA3033039C (hr) |
| CY (1) | CY1123238T1 (hr) |
| DK (1) | DK3500253T3 (hr) |
| EA (1) | EA032957B1 (hr) |
| ES (1) | ES2810983T3 (hr) |
| HR (1) | HRP20201262T1 (hr) |
| HU (1) | HUE052003T2 (hr) |
| IL (1) | IL264406B (hr) |
| LT (1) | LT3500253T (hr) |
| MA (1) | MA45990B1 (hr) |
| MD (1) | MD3500253T2 (hr) |
| ME (1) | ME03812B (hr) |
| MX (1) | MX2019001696A (hr) |
| NZ (1) | NZ750150A (hr) |
| PL (1) | PL3500253T3 (hr) |
| PT (1) | PT3500253T (hr) |
| RS (1) | RS60669B1 (hr) |
| SG (1) | SG11201900681SA (hr) |
| SI (1) | SI3500253T1 (hr) |
| WO (1) | WO2018033847A1 (hr) |
| ZA (1) | ZA201900467B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019229509A1 (en) * | 2018-05-31 | 2019-12-05 | Suven Life Sciences Limited | Method of treatment with histamine-3 receptor inverse agonist |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120035183A (ko) * | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| CN103443093B (zh) * | 2011-02-23 | 2015-02-25 | 苏文生命科学有限公司 | 作为组胺h3受体配体的化合物 |
| FR2974729B1 (fr) | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| SG11201601306QA (en) | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2017
- 2017-08-14 ME MEP-2020-167A patent/ME03812B/me unknown
- 2017-08-14 NZ NZ750150A patent/NZ750150A/en unknown
- 2017-08-14 US US16/320,949 patent/US10603323B2/en active Active
- 2017-08-14 SI SI201730360T patent/SI3500253T1/sl unknown
- 2017-08-14 HU HUE17768234A patent/HUE052003T2/hu unknown
- 2017-08-14 AU AU2017313427A patent/AU2017313427B2/en active Active
- 2017-08-14 MD MDE20190714T patent/MD3500253T2/ro unknown
- 2017-08-14 MA MA45990A patent/MA45990B1/fr unknown
- 2017-08-14 SG SG11201900681SA patent/SG11201900681SA/en unknown
- 2017-08-14 EP EP17768234.1A patent/EP3500253B1/en active Active
- 2017-08-14 CN CN201780049311.9A patent/CN109640975B/zh active Active
- 2017-08-14 RS RS20200949A patent/RS60669B1/sr unknown
- 2017-08-14 PL PL17768234T patent/PL3500253T3/pl unknown
- 2017-08-14 WO PCT/IB2017/054938 patent/WO2018033847A1/en active Search and Examination
- 2017-08-14 ES ES17768234T patent/ES2810983T3/es active Active
- 2017-08-14 BR BR112019002645A patent/BR112019002645A2/pt active Search and Examination
- 2017-08-14 LT LTEP17768234.1T patent/LT3500253T/lt unknown
- 2017-08-14 MX MX2019001696A patent/MX2019001696A/es active IP Right Grant
- 2017-08-14 EA EA201990480A patent/EA032957B1/ru unknown
- 2017-08-14 CA CA3033039A patent/CA3033039C/en active Active
- 2017-08-14 DK DK17768234.1T patent/DK3500253T3/da active
- 2017-08-14 KR KR1020197007056A patent/KR102039585B1/ko active IP Right Grant
- 2017-08-14 PT PT177682341T patent/PT3500253T/pt unknown
- 2017-08-14 JP JP2019506640A patent/JP6734470B2/ja active Active
-
2019
- 2019-01-22 IL IL264406A patent/IL264406B/en active IP Right Grant
- 2019-01-23 ZA ZA2019/00467A patent/ZA201900467B/en unknown
-
2020
- 2020-08-05 CY CY20201100725T patent/CY1123238T1/el unknown
- 2020-08-11 HR HRP20201262TT patent/HRP20201262T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021046A5 (hr) | ||
| HRP20110524T1 (hr) | Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju | |
| JP2009541443A5 (hr) | ||
| HRP20201412T1 (hr) | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda | |
| JP2015523407A5 (hr) | ||
| HRP20200872T1 (hr) | Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze | |
| JP2018168191A5 (hr) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2015083580A5 (hr) | ||
| NZ597241A (en) | Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor | |
| HRP20120144T1 (hr) | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost | |
| HRP20210640T1 (hr) | Kombinacija čistih 5-ht6 antagonista receptora sa nmda antagonistom receptora | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| JP2018537507A5 (hr) | ||
| HRP20121078T1 (hr) | Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| JP2021505575A5 (hr) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| HRP20191869T1 (hr) | Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora | |
| JP2020529995A5 (hr) | ||
| AR117655A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal |